Company

Board of Directors

  • Michael Altman, CFA

    Senior Analyst, Perceptive Advisors

    Michael Altman joined Perceptive in 2007 and is a senior analyst on the investment team. His focus is on medical devices, diagnostics, digital health and specialty pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Vensun Pharmaceuticals and Vitruvius Therapeutics.

    Michael Altman joined Perceptive in 2007 and is a senior analyst on the investment team. His focus is on medical devices, diagnostics, digital health and specialty pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Vensun Pharmaceuticals and Vitruvius Therapeutics.

  • Robert Langer, D.Sc.

    David H. Koch Institute Professor, Massachusetts Institute of Technology, Co-Founder

    Robert Langer is one of 13 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member. Dr. Langer has written more than 1,400 articles. He also has over 1,300 issued and pending patents worldwide. Dr. Langer's patents have been licensed or sublicensed to over 350 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 -- 2002 and as its Chairman from 1999-2002. Dr. Langer has received over 220 major awards. He is one of four living individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011). He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; the 2008 Millennium Prize, the world's largest technology prize; the 2012 Priestley Medal, the highest award of the American Chemical Society; and the 2015 Queen Elizabeth Prize for Engineering. Among his multiple accolades, Forbes Magazine selected Dr. Langer as “one of the 25 most important individuals in biotechnology in the world” and “one of the 15 innovators worldwide who will reinvent our future.” He holds 33 honorary doctorates. He received his Bachelor's Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.

    Robert Langer is one of 13 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member. Dr. Langer has written more than 1,400 articles. He also has over 1,300 issued and pending patents worldwide. Dr. Langer's patents have been licensed or sublicensed to over 350 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 -- 2002 and as its Chairman from 1999-2002. Dr. Langer has received over 220 major awards. He is one of four living individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011). He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; the 2008 Millennium Prize, the world's largest technology prize; the 2012 Priestley Medal, the highest award of the American Chemical Society; and the 2015 Queen Elizabeth Prize for Engineering. Among his multiple accolades, Forbes Magazine selected Dr. Langer as “one of the 25 most important individuals in biotechnology in the world” and “one of the 15 innovators worldwide who will reinvent our future.” He holds 33 honorary doctorates. He received his Bachelor's Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.

  • Maria Palasis, Ph.D.

    President and Chief Executive Officer

    Maria Palasis is an industry veteran in merging material science and drug-delivery innovation to create best-in-class therapies for patients. She brings nearly 25 years of healthcare industry experience to Lyra. A repeat entrepreneur, her transformative leadership as CEO, and previously CTO, of 480 Biomedical and Arsenal Medical resulted in >$160 million of external and non-dilutive funding and the advancement of multiple programs into the clinic. Earlier in her career, she managed a portfolio of external biotech and medical device investments at Boston Scientific and led the development of several combination therapies. She is an inventor on more than 120 issued and pending patents. Maria received her B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.

    Maria Palasis is an industry veteran in merging material science and drug-delivery innovation to create best-in-class therapies for patients. She brings nearly 25 years of healthcare industry experience to Lyra. A repeat entrepreneur, her transformative leadership as CEO, and previously CTO, of 480 Biomedical and Arsenal Medical resulted in >$160 million of external and non-dilutive funding and the advancement of multiple programs into the clinic. Earlier in her career, she managed a portfolio of external biotech and medical device investments at Boston Scientific and led the development of several combination therapies. She is an inventor on more than 120 issued and pending patents. Maria received her B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.

  • Carmichael Roberts, Ph.D.

    General Partner, North Bridge Venture Partners, Co-Founder

    Carmichael Roberts joined North Bridge Venture Partners in 2007, where he focuses mainly on early-stage companies that make products using unique chemistry and materials inventions. Prior to North Bridge, Dr. Roberts co-founded and served as the president and chief executive officer of Arsenal Medical. Dr. Roberts has co-founded other ventures, including several focused on life sciences. In 1999, Dr. Roberts was named one of the world’s top 100 young entrepreneurs by MIT’s Technology Review. Prior to his entrepreneurial career, Dr. Roberts worked in business development at GelTex Pharmaceuticals, which was acquired by Genzyme for $1.1 billion, and in new product and business development at Dow Chemical (formerly Union Carbide Corporation). Dr. Roberts received his B.S. and Ph.D. in organic chemistry from Duke University, and he completed his postdoctoral National Science Foundation fellowship at Harvard University. Dr. Roberts also holds an M.B.A. from the MIT Sloan School of Management. He serves as an advisor for MIT’s Deshpande Center for Technological Innovation, Harvard’s Nanoscale Science and Engineering Center and the schools of Science and Engineering at Duke University.

    Carmichael Roberts joined North Bridge Venture Partners in 2007, where he focuses mainly on early-stage companies that make products using unique chemistry and materials inventions. Prior to North Bridge, Dr. Roberts co-founded and served as the president and chief executive officer of Arsenal Medical. Dr. Roberts has co-founded other ventures, including several focused on life sciences. In 1999, Dr. Roberts was named one of the world’s top 100 young entrepreneurs by MIT’s Technology Review. Prior to his entrepreneurial career, Dr. Roberts worked in business development at GelTex Pharmaceuticals, which was acquired by Genzyme for $1.1 billion, and in new product and business development at Dow Chemical (formerly Union Carbide Corporation). Dr. Roberts received his B.S. and Ph.D. in organic chemistry from Duke University, and he completed his postdoctoral National Science Foundation fellowship at Harvard University. Dr. Roberts also holds an M.B.A. from the MIT Sloan School of Management. He serves as an advisor for MIT’s Deshpande Center for Technological Innovation, Harvard’s Nanoscale Science and Engineering Center and the schools of Science and Engineering at Duke University.

  • George Whitesides, Ph.D.

    Woodford L. and Ann A. Flowers University Professor, Harvard University, Co-Founder

    Dr. Whitesides joined Harvard’s department of chemistry in 1982 and served as department chairman from 1986 to 1989. From 1963 to 1982, he was a faculty member at Massachusetts Institute of Technology. Dr. Whitesides held advisory positions on the National Research Council, National Science Foundation and the Department of Defense’s Defense Advanced Research Projects Agency (DARPA), and he is a member of the American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering and the American Philosophical Society, among other organizations. He has received dozens of honors, including the American Chemical Society (ACS) Award in Pure Chemistry (1975), the Arthur C. Cope Award (1995), the DARPA Award for Significant Technical Achievement (1996), the National Medal of Science (1998), the Von Hippel Award (2000), the Kyoto Prize (2003), the Dan David Award (2005), the Welch Award (2005), the Priestley Award (2007), the American Institute of Chemists Gold Medal (2007), the Prince of Asturias Foundation Award (2008), the Nanoscience Prize (2008), the Wheland Medal (2008) and the Benjamin Franklin Medal in Chemistry (2009). George is a co-founder of a number of companies including Genzyme, GelTex, Theravance and Arsenal Medical. He received a Bachelor of Arts from Harvard University in 1960 and a doctorate from the California Institute of Technology in 1964.

    Dr. Whitesides joined Harvard’s department of chemistry in 1982 and served as department chairman from 1986 to 1989. From 1963 to 1982, he was a faculty member at Massachusetts Institute of Technology. Dr. Whitesides held advisory positions on the National Research Council, National Science Foundation and the Department of Defense’s Defense Advanced Research Projects Agency (DARPA), and he is a member of the American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering and the American Philosophical Society, among other organizations. He has received dozens of honors, including the American Chemical Society (ACS) Award in Pure Chemistry (1975), the Arthur C. Cope Award (1995), the DARPA Award for Significant Technical Achievement (1996), the National Medal of Science (1998), the Von Hippel Award (2000), the Kyoto Prize (2003), the Dan David Award (2005), the Welch Award (2005), the Priestley Award (2007), the American Institute of Chemists Gold Medal (2007), the Prince of Asturias Foundation Award (2008), the Nanoscience Prize (2008), the Wheland Medal (2008) and the Benjamin Franklin Medal in Chemistry (2009). George is a co-founder of a number of companies including Genzyme, GelTex, Theravance and Arsenal Medical. He received a Bachelor of Arts from Harvard University in 1960 and a doctorate from the California Institute of Technology in 1964.